PROK
ProKidney Corp.
ProKidney Corp. (PROK) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 40.0, with 0/3 trend checks passing.
PROK with MA50 and MA200
Key levels & signals
ProKidney Corp. (PROK) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $1.60, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 10.1% and below the 200-day moving average by 26.7%.
PROK currently has an RSI reading of 40.0, which leans a little softer than neutral. That does not automatically make the chart bearish, but it does suggest momentum is not especially strong right now.
For traders reviewing PROK next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About ProKidney Corp.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
PROK shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about PROK
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.